Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies

Detalles Bibliográficos
Autores principales: Nahas, Stephanie J., Naegel, Steffen, Cohen, Joshua M., Ning, Xiaoping, Janka, Lindsay, Campos, Verena Ramirez, Krasenbaum, Lynda J., Holle-Lee, Dagny, Kudrow, David, Lampl, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2022
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112594/
https://www.ncbi.nlm.nih.gov/pubmed/35581545
http://dx.doi.org/10.1186/s10194-022-01423-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112594/
https://www.ncbi.nlm.nih.gov/pubmed/35581545
http://dx.doi.org/10.1186/s10194-022-01423-x

Ejemplares similares